Allogran-N Shows Equivalence To Allograft In Revision Hip Surgery In 13 Year Follow Up Study
Posted June 2009

A recent study carried out by the Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, UK, has shown that Allogran-N can be used in combination with allograft for revision hip surgery. It concludes that Allogran-N can be a viable alternative to allograft in the event of shortage and help decrease the incidence of allograft transmitted infections by halving the number of bone donors in any one revision case.

The study involved a 13 year follow up of sixty five patients having revision hip arthroplasty using impaction grafting with either allograft alone or a 50:50 mixture of allograft and Allogran-N granules. In both groups of patients, the average post-operative hip score was 64 points and implant survival at 13 years was around 83%.

The authors concluded that long term prosthesis survival and function following revision hip arthroplasty with a 50:50 mixture of allograft and Allogran-N are comparable to allograft alone.

Allogran-N hydroxyapatite granules are fully synthetic and are engineered for compaction resistance. Allogran-N is CE marked and cleared by FDA for use in conjunction with allograft material. Allogran-N reduces the surgeon’s reliance on allograft tissue, presenting both a major cost saving and a reduction in the risks associated with its use.

Reference:
Tajeshwar S. Aulakh, Narlaka Jayasekera, Jan-Herman Kuiper, James B. Richardson.
Long-term clinical outcomes following the use of synthetic hydroxyapatite and bone graft in impaction in revision hip arthroplasty. Biomaterials 30 (2009) 1732-1738